Document Detail

Clinical and economic impact of etanercept in real-life: A prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER).
MedLine Citation:
PMID:  24334009     Owner:  NLM     Status:  Publisher    
Background: Real-life data on the therapeutic effectiveness and costs of etanercept are scarce. Objectives: To assess the clinical and economic impact of etanercept in patients with psoriasis in Denmark and Norway. Material & methods: This prospective, non-interventional study in a private dermatologist care setting in Denmark and Norway included patients ≥18 years with moderate to severe plaque psoriasis, selected for treatment with etanercept. Assessments during 1 year from etanercept initiation included Dermatology Life Quality Index (DLQI), Self-Administered Psoriasis Area and Severity Index (SAPASI) and adverse events. Direct and indirect costs were calculated. Results: 163 subjects were enrolled. Baseline mean SAPASI was 19.1 . Proportion of patients with ≥50% decrease in SAPASI from baseline was 85% and 81% at weeks 24 and 52. DLQI decreased significantly from 11.4 (7.0) to 3.2 (4.3) and 3.7 (4.6) at weeks 24 and 52. Total annual costs increased from 78,000 to 286,000 DKK (p<0.0001), mainly due to the cost of etanercept. Outpatient-care costs and loss-of-productivity costs decreased from 9,500 to 5,000 (p = 0.0002), and from 33,000 to 18,000 DKK (p = 0.0105), respectively. The decrease in costs was more pronounced in patients who also had psoriatic arthritis. Cost increase was greatest during the first 6 months. Conclusion: Etanercept treatment was associated with decreased psoriasis severity and improved quality of life. Cost increase was driven by medication, while costs of outpatient care and loss-of-productivity decreased. Maintained improved quality of life was accompanied by decreasing cost during the second 6 month period of etanercept treatment. There were no new safety signals reported.
Christian Grønhøj Larsen; Peter Hundevadt Andersen; Henrik Lorentzen; Claus Zachariae; Theis Huldt-Nystrøm; Lars Kåre Dotterud; Rose-Marie Lindkvist; Susanne Qvitzau
Related Documents :
22948099 - Extracorporeal photochemotherapy as systemic monotherapy of severe, refractory atopic d...
10982509 - Simplified admission criterion for predicting severe complications of gallstone pancrea...
7827299 - Dissolution of pancreatic stones by oral trimethadione in patients with chronic calcifi...
24685379 - Five-year real world outcomes of geoform ring implantation in patients with ischemic mi...
20173669 - Acute pancreatitis in patients operated on for intraductal papillary mucinous neoplasms...
7904499 - Carcinoma of the ampulla of vater: long-term survival after surgical treatment.
8368229 - Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.
8119019 - Incidence of posthospitalization proximal deep venous thrombosis after total hip arthro...
18675689 - Effect of eradication of helicobacter pylori on incidence of metachronous gastric carci...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-12-12
Journal Detail:
Title:  European journal of dermatology : EJD     Volume:  -     ISSN:  1952-4013     ISO Abbreviation:  Eur J Dermatol     Publication Date:  2013 Dec 
Date Detail:
Created Date:  2013-12-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9206420     Medline TA:  Eur J Dermatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Synthesis, photochemistry, DNA cleavage/binding and cytotoxic properties of fluorescent quinoxaline ...
Next Document:  Airflow pattern complexity during resting breathing in patients with COPD: Effect of airway obstruct...